A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma.

Jerónimo Rafael Rodríguez-CidSonia Carrasco-Cara ChardsIván Romarico González-EspinozaVanessa García-MontesJulio César Garibay-DíazOsvaldo Hernández-FloresRodrigo Riera-SalaAnna Gozalishvili-BonchevaJorge Arturo Alatorre-AlexanderLuis Manuel Martínez-BarreraCarla Paola Sánchez-RíosAdriana Martinez-CamachoJosé Fabián Martínez-Herrera Jordi Guzmán-CastaRodrigo Rafael Flores-MariñelarenaJulián Diaz-RicoPatricio Santillán-Doherty

Published in: Lung cancer management (2021)

The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
single cell
prognostic factors
peritoneal dialysis
emergency department
stem cells
mesenchymal stem cells
free survival
smoking cessation
combination therapy
adverse drug